Keyword: Endo

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Many years into an investigation over a "pay-for-delay" payment on Opana ER, the FTC says Impax violated competition law.

Endo says it has dropped its $190 million buyout of sterile injectables company Somerset Therapeutics as approvals from India became uncertain.

Thanks to groundwork laid by the feds, UnitedHealthcare is suing dozens of generics companies for alleged price fixing—and it wants its money back.

Endo's new awareness ad features older men examining irregularly curved produce to underscore its message about the rare disease.

Stability has finally returned to the U.S. generics market, which had been suffering what Teva CEO Kåre Schultz called “a classical negative death spiral."

Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.

Endo’s lawsuit to keep the FDA from giving bulk compounders the ability to compete with one of its key drugs is off for now.

Staring at 1,000 opioid lawsuits, Endo is said to be trying to negotiate its own settlement deal with lawyers for states and cities.

AndroGel plaintiffs and drugmaker AbbVie have progressed in settlement talks, and a judge stayed further proceedings so they can work out a deal.